The recruitment has been finalized and the BARDA trial extension funding agreement goes to Sep 2025. The Company has a budget for this and I doubt they will extend if they have statistically significant enrollment covered. The timely conclusion of the trial is important for reimbursement baselines and further uptake where insurers and hospitals have discretion on treatment and supply. The relevant trial for ulcers will also apply similarly to the Diabetic Ulcer market.
I expect the company's efforts to support learning opportunities and word-of-mouth recommendations is working there as it has in many other jurisdictions.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)